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BACKGROUND: An increasing proportion of patients are exposed to anthracyclines and/or taxanes in the adjuvant or neoadjuvant
setting. Re-exposure in the metastatic stage is limited by drug resistance, thus evaluation of non-cross-resistant regimens is mandatory.
METHODS: Anthracycline-pretreated patients were randomly assigned to three gemcitabine-based regimens. Chemotherapy consisted
of gemcitabine 1.000mgm
 2 plus vinorelbin 25mgm
 2 on days 1þ8 (GemVin), or plus cisplatin 30mgm
 2 on days 1þ8
(GemCis), or plus capecitabine 650mgm
 2 b.i.d. orally days 1–14 (GemCap), q3w. The primary end point was response rate.
RESULTS: A total of 141 patients were recruited on the trial. The overall response rates were 39.0% (GemVin), 47.7% (GemCis) and
34.7% (GemCap). Median progression-free survival was estimated with 5.7, 6.9 and 8.3 months, respectively. Corresponding median
survival times were 17.5 (GemVin), 13.0 (GemCis) and 19.4 months (GemCap). Neutropenia Xgrade 3 occurred in 16.7%
(Gem/Vin), 4.4% (GemCis) and 0% (Gem/Cap), whereas non-haematological toxicities were rarely severe except grade 3 hand–foot
syndrome in 2.0% of the GemCap patients (per patient analysis).
CONCLUSIONS: This randomised phase II trial has revealed comparable results for three gemcitabine-based regimens regarding
treatment efficacy and toxicity. Gemcitabine-based chemotherapy appears to be a worthwhile treatment option for pretreated
patients with metastatic breast cancer.
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Strategies in patients with advanced breast cancer are confounded
by the increasing exposure of patients to chemotherapy in the
adjuvant setting. Nevertheless, two general strategies are apparent
and should be followed: (1) improving treatment efficacy by
exploring new drugs and drug combinations, and (2) ensuring that
efficacy is improved with the lowest cost to quality of life.
Gemcitabine as a single agent has induced overall response rates
of 0–37% in first-line treatment, whereas the response rates in the
second- or third-line therapy were 26 and 13% (Brodowicz et al,
2000; Spielmann et al, 2001; Blackstein et al, 2002; Heinemann,
2003, 2005; Modi et al, 2005). In studies limited to second- or
third-line therapy after anthracycline and/or taxane exposure,
response rates of 0–29% and median time to progression of 2–6
months were achieved (Spielmann et al, 2001; Modi et al, 2005;
Heinemann et al, 2006; Seo et al, 2007). Several considerations
support the use of gemcitabine and a platinum salt in the salvage
treatment of metastatic breast cancer (MBC): First, in vitro studies
indicate additive or synergistic activity that was most pronounced
in platinum-resistant cell lines and was found to be due to an
increased formation and an impaired repair of platinum–DNA
adducts (Peters et al, 1995; van Moorsel et al, 1997). Second,
gemcitabine and the platinum salts are usually not included into
adjuvant or neoadjuvant chemotherapy. Therefore, resistance to
either drug is unlikely to occur. Third, studies investigating the
combination have shown minimal overlapping toxicity, suggesting
an acceptable toxicity profile even in intensively pretreated
patients. The combination of gemcitabine and cisplatin was shown
to be effective in several trials, inducing response rates between
30 and 52% in patients pretreated with taxanes and/or anthracy-
clines (Kolaric and Vukas, 1991; Chitapanarux et al, 2006; Fuentes
et al, 2006; Heinemann et al, 2006; Kim et al, 2008).
Vinorelbine has shown good efficacy as first-line treatment
(40–60%), activity after anthracycline pretreatment has only been
moderate (16%) (Degardin et al, 1994; Jones et al, 1995;
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sGregory and Smith, 2000). The dose-limiting toxicity of vinor-
elbine is in the form of non-cumulative haematotoxicity. The
potential of adding gemcitabine to vinorelbine has been explored
in various phase II studies (Nicolaides et al, 2000; Valenza et al,
2000; Park et al, 2009; Shehata et al, 2010). Haider et al (1999)
conducted a study that evaluated gemcitabine plus vinorelbine
(GemVin) separately as first-line therapy. In the subgroup of
45 chemonaive patients the overall response rate was 56%. Two
additional studies that applied GemVin for second-line therapy
(after anthracyclines±taxanes) achieved response rates of 48
and 54%, respectively (Haider et al, 1999; Valenza et al, 2000;
Stathopoulos et al, 2002; Shehata et al, 2010). These studies
demonstrate that the combination of GemVin is active not only as
first-line treatment but also after pretreatment with anthracycline-
or anthracycline/taxane-based regimens. Gemcitabine and capeci-
tabine (GemCap) are among the few agents active in patients with
MBC progressing after therapy with anthracyclines and taxanes.
Andres et al (2005) conducted a phase II trial of GemCap in
patients with disease progression after treatment with anthracy-
clines and taxanes. The response rate was 48.7%. Median time to
progression was 5 months (range, 1–26 months) and the median
overall survival duration was 10 months. Another study by
Ciruelos et al (2009) investigated the combination in the first-
and second-line setting with a response rate of 61 and 48.5%,
respectively. Most frequent grade 3–4 observed toxic effects were
neutropenia (60%) and hand–foot syndrome (16%). The authors
concluded that the combination of GemCap is an active and
safe regimen in anthracycline-pretreated breast cancer patients
(Campos et al, 2001; Schilsky et al, 2001; Andres et al, 2005;
Ciruelos et al, 2009; Malmstrom et al, 2010).
Taken together, these data provided the basis for this open,
randomised phase II study, which investigated the efficacy of three
different gemcitabine-based regimens for patients with MBC.
PATIENTS AND METHODS
Patient population
One-hundred and forty-one patients with histologically confirmed
MBC were recruited on a treatment protocol approved by the
independent ethics committees of all participating centres and was
conducted according to the International Conference on Harmonisa-
tion (ICH) – Good Clinical Practice (GCP) guidelines. All patients
were required to give written informed consent before study entry.
The study was registered by the US National Institutes of Health
(http://clinicaltrials.gov/; ClinicalTrials.gov Identifier: NCT00480597).
Patients eligible for the trial required one previous anthracycline-
based regimen (in the adjuvant or in the metastatic setting).
There was no limit on number of previous chemotherapy regimens
(except gemcitabine-, vinorelbine-, cisplatin- or capecitabine-
containing regimens), or on the number of previous hormonal
therapies. Moreover, immunotherapy or local radiotherapy was
allowed. Patients were required to have at least one bi-dimensionally
measurable lesion outside a previous radiation port. Other eligibility
criteria included age X18 and p70 years, Karnofsky performance
status X70%, minimal life expectancy of 12 weeks, and adequate
haematological, renal, cardiac and hepatic function (leukocyte
count X3.0 10
9l
 1 or absolute neutrophil count X2 10
9l
 1;
platelet count X100 10
9l
 1;h a e m o g l o b i nX8gdl
 1; total serum
bilirubin p1.25 upper limit of normal (ULN) in the absence of
liver metastasis or p3.0 ULN in the presence of liver metastasis;
transaminase (ALT, AST) level p3 ULN in the absence of liver
metastasis or p5 ULN in the presence of liver metastasis; and
alkaline phosphatase level p2.5 ULN). Creatinine clearance was
required to exceed 60mlmin
 1.
Patients were not eligible for study enrolment if they were
pregnant, lactating or refused effective contraception, if they had
bone metastasis only, known brain metastases or a secondary
malignancy, history of another primary malignant disease other
than in situ carcinoma of the uterine cervix or adequately treated
basal cell skin cancer, active infection or any other concomitant
severe clinical condition making implementation of the protocol
including prehydration difficult. Administration of other cyto-
toxic, immune or hormonal agents or radiation therapy was not
permitted during the study, with the exception of contraceptives,
corticosteroids given as antiemetic treatment, or local palliative
radiation. Patients were not eligible if they had received prior
gemcitabine, vinorelbine, cisplatin or capecitabine. Finally, patients
with a history of DPD-deficiency were ineligible for the trial.
Patient assessment
Patients were evaluated on a regular basis during treatment. The
following assessments were performed before each 3-week cycle:
physical examination, complete blood count, serum chemistry
(including creatinine clearance) and assessment of toxicities.
During the initial phase of treatment, complete blood counts were
performed twice weekly to determine the nadir values. If the
haematological values had not recovered by the time of scheduled
treatment, the complete blood count was repeated every week until
recovery of leukocyte count to 3.0 10
9l
 1 and platelets to
X100 10
9l
 1.
Baseline tumour assessment was performed within 2 weeks of
the start of treatment using imaging procedures, such as
ultrasound, computerised tomography or magnetic resonance
imaging. Tumour assessments were repeated after every three
cycles of therapy, applying the initially used imaging procedure.
World Health Organization and NCN-CTC criteria (3.0) were used
for the assessment of tumour response and toxicity grading (Ajani
et al, 1990).
In addition, time to response (time from the start of therapy to
first documentation of objective response), duration of response
(time from the first documentation of objective response to first
evidence of progressive disease), time to tumour progression (time
from the start of therapy to first evidence of progressive disease or
last follow-up) and survival (time from the start of therapy to
death) were measured (intent to treat).
Treatment schedule
Patients were randomly assigned to one of the following treatment
schedules:
1. Gemcitabine 1000mgm
 2 (soluted in 250ml of 0.9% saline) given
a sa3 0 - m i ni n f u s i o no nd a y s1 þ8 followed by vinorelbine
25mgm
 2 (soluted in 100ml of 0.9% saline) given as a 6–10min
infusion on days 1þ8 of a 3-week treatment cycle.
2. Gemcitabine 1000mgm
 2 (soluted in 250ml of 0.9% saline)
given as a 30-min infusion on days 1þ8 plus cisplatin
30mgm
 2 (soluted in 500ml of 0.9% saline) given as a
60-min infusion on days 1þ8 of a 3-week treatment cycle.
Patients within this treatment arm received pre- and posthy-
dration with 1lm
 2 0.9% saline i.v. over 2h or orally 2–3l
mineral water over 8h. Immediately prior to cisplatin 20mg of
furosemide was applied by i.v. injection.
3. Gemcitabine 1000mgm
 2 (soluted in 250ml of 0.9% saline)
given as a 30-min infusion on days 1þ8 plus capecitabine
1.300mgm
 2 (divided in 2 daily doses) given orally on days
1–14 of a 3-week treatment cycle.
All patients received antiemetics (mainly 5-HT3 antagonists)
according to the local standards. Patients within the cisplatin
regimen were allowed to receive corticosteroids also.
Treatment was continued until disease progression or the
occurrence of unacceptable toxicity. In case of a partial response or
stable disease a maximum of 6 cycles were planned. If patients
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(CRþ2 cycles; maximum 8 cycles).
Dose adjustments
Dose adjustments were made on the basis of leukocyte and platelet
counts on the day of treatment and clinical assessments of non-
haematological toxicities.
A full dose was applied when the leukocyte count was
42.5 10
9l
 1, while the platelet count exceeded 100 10
9l
 1;
the doses of both drugs were reduced by 25% if the leuko-
cyte count was between 2.0 and 2.5 10
9l
 1, while the platelet
count exceeded 100 10
9l
 1; and if the leukocyte count was
o2.0 10
9l
 1 or the platelet count o100 10
9l
 1, the doses of
both drugs were omitted. Omitted day-8 doses were not replaced
and the next cycle was given timely as scheduled but at reduced
doses. If the patient tolerated the dose-modified treatment well, a
re-increase of dosage could be attempted in the following cycle.
The use of haematopoietic growth factors was allowed in patients
with prolonged haematopoietic recovery. If any grade 3 toxicity
except nausea/vomiting occurred, drug doses were reduced by
50%; while the patient was out of study in case of any grade 4 non-
haematological toxicity. A full dose was applied if any grade 0–2
toxicity except nausea/vomiting (grade 3) occurred.
Patients who were randomised to cisplatin were required to have a
creatinine clearance, which exceeds 60mlmin
 1 during treatment,
otherwise they were out of study. Creatinine clearance was estimated
according to the recommendation of the ‘National Kidney Disease
Education Program’ and the ‘Modification of Diet in Renal Disease-
study’. The glomerular filtration rate (GFR) was calculated by the
MDRD formula: GFR (ml per min per 1.73m
2)¼186 C
 1.154
(mgdl
 1) age
 0.203 (years) k;C¼serum creatinine concentration;
k¼correction factor (female 0.742; male 1.0).
Biometrical analysis
The primary objective of the study was to determine the objective
response rate to the study treatment. Secondary end points
included time to progression, survival and toxicity.
Simon’s optimal two-stage design was used to ensure that the
number of patients exposed to this therapy was minimised should
the therapy prove ineffective (Simon, 1989). The study was
planned to distinguish between a clinically uninteresting response
rate of 20% (null hypothesis) and a clinically interesting response
rate of 40% (alternative hypothesis). With the type I error being
5% and the type II error 10%, 13 patients were to be enrolled
during the first step and an additional 30 patients during the
second step. If three or less responses occurred among the first
13 patients or 12 or less responses in the total population of
43 patients, the treatment had to be judged ineffective and enrolment
stopped. Assuming a dropout rate of 10%, it was planned to enrol a
total of 47 patients on each treatment arm (3 47¼141 patients).
The determination of the 95% confidential intervals (CIs)
resulted by the exact method of Clopper/Pearson.
Time-to-event end points were calculated according to the
method of Kaplan and Meier (1959). Patients who received at least
one treatment cycle were evaluable for toxicity, and those who had
received at least two treatment cycles or those who progressed after
the first cycle were evaluable for response.
RESULTS
Patient characteristics
One-hundred and forty-one eligible patients were recruited
between 2003 and 2006 from 24 German centres. Because of
protocol violation in six cases (inclusion criteria) and one written
informed consent refusal, a total of 134 patients were evaluated for
the primary end point (Figure 1).
Median age was 58 years (GemVin), 60 years (gemcitabine plus
cisplatin, GemCis) and 60 years (GemCap), respectively. All
patients had previously received prior anthracyclines either in
the (neo-)adjuvant or the metastatic setting. Approximately 40% of
the patients had received both, an anthracycline- and a taxane-
based regimen. Moreover, a majority of the patients presented with
visceral metastases (480%) and B75% had more than one
metastatic site. About a third of the patients received the study
medication as first-line regimen for metastatic disease.
Detailed demography and baseline characteristics are shown in
Table 1.
Treatment delivery
In total, 200 cycles of GemVin, 190 cycles of GemCis and 207 cycles
of GemCap were applied. Patients received a median number of
6 cycles (GemVin), 4.5 cycles (GemCis) and 5 cycles (GemCap).
Dose reductions and delays were not significantly different among
the treatment arms. An increased rate of day-8 omissions
contributed to a significantly lower relative dose intensity within
the cisplatin combination (81.3 %) compared with 94% within the
capecitabine regimen (relative dose intensity, significance test w
2
for all arms, P¼0.003; vinorelbine vs cisplatin, P¼0.45; vinorelbin
vs capecitabine, P¼0.14; cisplatin vs capecitabine, P¼0.0003).
Detailed information regarding medication is given in Table 2.
Efficacy – response and survival
With a response rate of 39.0%, 95% CI: 24.2–55.5 (GemVin);
47.7%, 95% CI: 32.5–63.3 (GemCis); and 34.7%, 95% CI: 21.7–49.6
(GemCap), there was no striking difference regarding the primary
objective among the three study arms. Overall, the disease control
rate (objective response plus stable disease) was 63.4% (GemVin),
56.8% (GemCis) and 59.2% (GemCap), respectively (Table 3).
A detailed analysis of response with regard to triple negative
patients was undertaken. The corresponding response rates were
11.1%, 95% CI: 0.3–48.3 (GemVin); 58.3%, 95% CI: 27.7–84.8
(GemCis); and 53.3%, 95% CI: 27.0–78.7 (GemCap).
The median follow-up interval for the whole study population
was 11.1 months (95% CI: 7.6–14.6 months). Median duration of
response was 6.9 months, 95% CI: 5.1–8.1 (GemVin); 6.9 months,
95% CI: 5.5–8.8 (GemCis); and 8.3 months, 95% CI: 7.1–10.6
Randomised
(n =141)
Vinorelbine
(n = 46) 
Cisplatin
(n = 45)
Capecitabine
(n = 50)
Safety
(n = 42)
Safety
(n = 45)
Safety
(n = 49)
Efficacy
(n = 41)
Efficacy
(n = 44)
Efficacy
(n = 49)
Did not meet
inclusion criteria,
n = 1
Did not meet
inclusion criteria,
n = 0
Did not meet
inclusion criteria,
n = 1
Did not meet
inclusion criteria,
n = 0
Did not meet
inclusion criteria,
n = 4
Did not meet
inclusion criteria,
n = 1
Figure 1 Flow of participants.
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s(GemCap). The median progression-free survival was 5.7 months,
95% CI: 3.9–8.2 (GemVin); 6.9 months, 95% CI: 5.8–8.8 (GemCis);
and 8.3 months, 95% CI: 4.3–9.6 (GemCap), and the median
overall survival was estimated with 17.5 months, 95% CI: 12.2–30.0
(GemVin); 13.0 months, 95% CI: 11.0–19.2 (GemCis); and 19.4
months, 95% CI: 16.6–22.0 (GemCap).
Progression-free and overall survival curves are shown in
Figures 2 and 3.
Toxicity
The predominant haematological toxicity was grade 3–4 neutro-
penia, which occurred in 16.6% of the patients within the GemVin
arm. This was significantly higher compared with the rate of
neutropenia within the GemCap arm (0%; P¼0.004). Moreover,
only 4.4% of the patients who received the cisplatin combination
experienced grade 3–4 neutropenia. Febrile neutropenia was
observed in none of the included patients. The rate of grade
3 and 4 anaemia and thrombopenia was low and comparable
within the treatment arms.
Non-haematological toxicity was considered mild to moderate.
Grade 3 and 4 non-haematological toxicity was observed in few
patients including hand–foot syndrome (2%) and dermatological
side effects (4.1%), predominantly in those patients who received
capecitabine. Any other non-haematological toxicity was compar-
able among the study population.
Detailed information of haematological and non-haematological
toxicity is given in Table 4.
DISCUSSION
With the increasing use of anthracycline- and taxane-based
regimens in the neoadjuvant and adjuvant setting and their
established application in the treatment of the advanced and
metastatic stages of breast cancer, there is a clear need for non-
cross-resistant further-line regimens.
Table 1 Patients demography and characteristics
Gemcitabine and Vinorelbine Gemcitabine and Cisplatin Gemcitabine and Capecitabine
Randomised patients (n)4 6 4 5 5 0
Median age (years) (range) 58 (38–77) 60 (36–74) 60 (34–78)
Median KPS (%) (range) 100 (70–100) 95 (70–100) 95 (70–100)
N % N % N %
Tumour metastatic sites
Visceral 41 89.1 37 82.2 45 90.0
Non-visceral only 5 10.9 8 17.8 5 10.0
Number of metastatic sites
1 12 26.1 13 28.9 12 24.0
2 19 41.3 24 53.3 24 48.0
X3 14 30.4 8 17.8 13 26.0
Unknown 1 2.2 1 2.0
Hormone receptor status
Positive 28 60.9 26 57.8 25 50.0
Negative 16 34.8 18 40.0 18 36.0
Unknown 2 4.4 1 2.2 7 14.0
HER2 status
Positive (IHC3+, FISH+) 4 8.7 7 15.6 5 10.0
Negative 32 69.6 30 66.7 35 70.0
Unknown 10 21.7 8 17.8 10 20.0
Menopausal status
Premenopausal 10 21.7 8 17.8 4 8.0
Postmenopausal 19
a 41.3 23 51.1 34
a 68.0
Unknown 17 37.0 14 31.1 12 24.0
Prior hormonal treatment
Prior hormonal treatment 26 56.5 27 60.0 28 56.0
Unknown 2 4.45 — — 1 2.0
Prior chemotherapy (CTX)
Prior anthracyclines 24 52.2 26 57.8 31 62.0
Prior anthracyclines+taxanes 20 43.5 19 42.2 19 38.0
Prior taxanes 1 2.2 — — — —
Unknown 1 2.2 — — — —
Prior (neo)adjuvant CTX 33 71.7 32 71.1 39 78.0
Line of CTX for MBC
1st line 18 39.1 15 33.3 18 36.0
2nd line 15 32.6 13 28.9 17 34.0
X3rd line 11 23.9 8 17.8 10 20.0
Unknown 2
b 4.4 9
b 20.0 5 10.0
Abbreviations: FISH¼fluorescence in situ hybridisation; HER2¼human epidermal growth factor receptor 2; IHC3þ¼immunohistochemistry (DAKO 3þ); KPS¼Karnofsky
performance scale; MBC¼metastatic breast cancer.
aStatistical significant (P¼0.01).
bStatistical significant (P¼0.03).
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anthracycline- and taxane-pretreated patients, capecitabine has
become a widely accepted agent in this setting. Response rates in
the range of 26–52% and time to progression of 3.6–8.9 months
were reported in numerous phase II and III trials (Oshaughnessy
et al, 2001; Ahn et al, 2004; Batista et al, 2004; Lee et al, 2004; Wist
et al, 2004). The combination of GemCap was investigated in some
small phase II studies. Patients who had received that combination
as first-line regimen for MBC experienced a high response rate of
61%, whereas the response rate was 41–48.7% for those who had
already received anthracyclines and/or taxanes for metastatic
disease (Andres et al, 2005; Ciruelos et al, 2009; Malmstrom et al,
Table 3 Efficacy – response rates
Gemcitabine and Vinorelbine Gemcitabine and Cisplatin Gemcitabine and Capecitabine
N % 95% CI N % 95% CI N % 95% CI
CR 3 7.3 1.5–19.9 4 9.1 2.5–21.7 4 8.2 2.3–19.6
PR 13 31.7 18.1–48.1 17 38.6 24.4–54.5 13 26.5 15.0–41.1
ORR 16 39.0 24.2–55.5 21 47.7 32.5–63.3 17 34.7 21.7–49.6
SD 10 24.4 12.4–40.3 4 9.1 2.5–21.7 12 24.5 13.3–38.9
PD 11 26.8 14.2–42.9 11 25.0 13.2–40.3 12 24.5 13.3–38.9
NE 4 9.8 2.7–23.1 8 18.2 8.2–32.7 8 16.3 7.3–29.7
All 41 100.0 44 100.0 49 100.0
Abbreviations: CI¼confidence interval; CR¼complete remission; NE¼not evaluable by Fishers exact test; ORR¼overall response rate; PD¼progressive disease; PR¼partial
response; SD¼stable disease.
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Figure 2 Progression-free survival.
Table 2 Medication, dose adjustments and delays
Gemcitabine and Vinorelbine Gemcitabine and Cisplatin Gemcitabine and Capecitabine
Number of cycles applied
Total 200 190 207
Median/patient completed (range) 6.0 (1–8) 4.5 (1–8) 5.0 (1–8)
N % N % N %
Doses reduced, delayed or both
Day 1 52 26.0 57 30.0 56 27.1
Day 8 56 28.0 58 30.5 61 29.5
Dose omitted
Day 1 1 0.5
Day 8 17 8.5 27 14.2 9 4.4
Dose intensity gemcitabine
Planned dose (mgm
 2 per week) 666.7 666.7 666.7
Actual median dose (mgm
 2 per week) (range) 600.0 (307–684) 541.6 (309–679) 618.7 (274–698)
Relative dose intensity (actual/planned  100) 90.0 (46–103) 81.2 (46–102) 92.8 (41–105)
Dose intensity second substance
Planned dose (mgm
 2 per week) 16.7 20.0 6066.7
Actual median dose (mgm
 2 per week) (range) 15.0 (7–17) 16.3 (9–20) 5702.0 (2885–7778)
Relative dose intensity (actual/planned  100) 90.0 (42–104) 81.3
a (46–101) 94.0
a (48–128)
aStatistical significant (P¼0.0003) by Fishers exact test.
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Figure 3 Overall survival.
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(95% CI: 21.7–49.6) within the present trial seems to be
comparable with these data. The good tolerability of this regimen
was documented by the absence of severe neutropenia (grade 3–4
0%) and the low rate of severe hand–foot syndrome (2.0%).
Discrepancies regarding the toxicity profile are partly explained by
differences within the schedules, as previous investigators reported
severe neutropenia in up to 60% of the patients and a consistent
rate of hand–foot syndrome of about 15% (Andres et al, 2005;
Ciruelos et al, 2009; Malmstrom et al, 2010).
The preclinical rationale for a combination of gemcitabine with
a platinum analogue is supported by the synergistic interaction of
both agents (Peters et al, 1995; van Moorsel et al, 1997; Achanta
et al, 2001). Several clinical studies performed with various
schedules have demonstrated that the combination of gemcitabine
and platin is highly active not only in first-line treatment, but also
in patients previously exposed to anthracyclines and/or taxanes
(Nagourney et al, 2004, 2008; Nasr et al, 2004; Silva et al, 2004;
Alauddin and Shaharyar, 2005; Burch et al, 2005; Stemmler
et al, 2005; Chitapanarux et al, 2006; Demiray et al, 2006; Fuentes
et al, 2006; Heinemann et al, 2006; Yardley et al, 2006; Laessig et al,
2007; Moura et al, 2007; Seo et al, 2007; Kim et al, 2008; Loesch
et al, 2008; Chew et al, 2009; Somali et al, 2009). The remission
rate of the combination in the present trial was 47.7% (95% CI:
32.5–63.3), which compared favourably to reported remission
rates of 21.5–69.2% in the first- and second-line setting published
by other investigators (Nagourney et al, 2004, 2008; Nasr et al,
2004; Silva et al, 2004; Alauddin and Shaharyar, 2005; Burch
et al, 2005; Stemmler et al, 2005; Chitapanarux et al, 2006;
Demiray et al, 2006; Fuentes et al, 2006; Heinemann et al, 2006;
Yardley et al, 2006; Laessig et al, 2007; Moura et al, 2007; Seo et al,
2007; Kim et al, 2008; Loesch et al, 2008; Chew et al, 2009; Somali
et al, 2009). As reported by Koshy et al (2010), the schedule has
proven sustained efficacy with a response rate of 58.3% (95% CI:
27.7–84.8) even in those with triple-negative breast cancer
(TNBC). This finding seems to be reaffirmed in the present trial
with a response rate of 58.3% (95% CI: 27.7–84.8) in the sub-
group of TNBC patients. Regarding treatment-associated toxicity,
GemCis must be considered as well tolerable. Compared with
previously reported studies, the rate of severe (grade 3 and 4)
neutropenia and thrombocytopenia was rather low in our study
with 4.4 and 6.7%, respectively.
Finally, the study arm of GemVin within this study yielded a
response rate of 39.0% (95% CI: 24.2–55.5), which is also in
a range previously published in pretreated patients with MBC
(22–55.5%; Haider et al, 1999; Nicolaides et al, 2000; Valenza et al,
2000; Stathopoulos et al, 2002; Park et al, 2009; Shehata et al,
2010). Comparably to those studies, the main side effect was grade
3 and 4 neutropenia, but the incidence was considerably lower in
our trial (present trial: 16.7, 0% febrile neutropenia vs literature:
42–48%, up to 11% febrile neutropenia). Non-haematological
toxicity was generally mild, but included grade 3 and 4 nausea and
vomiting in few patients with 4.8 and 2.4%, respectively.
In summary, there was no striking difference with regard to
any efficacy parameter in terms of response rate, progression-free
or overall survival. These results compared favourably with those
published by other investigators (Nicolaides et al, 2000; Mohran,
2004; Alauddin and Shaharyar, 2005; Andres et al, 2005;
Burch et al, 2005; Stemmler et al, 2005; Demiray et al, 2006;
Fuentes et al, 2006; Heinemann et al, 2006; Moura et al, 2007; Seo
et al, 2007; Kim et al, 2008; Chew et al, 2009; Ciruelos et al,
2009; Park et al, 2009; Somali et al, 2009; Koshy et al, 2010;
Table 4 Adverse reactions, per-patient-analysis, toxicity grade X3
Gem/Vin toxicity
grade X3
Gem/Cis toxicity
grade X3
Gem/Cap toxicity
grade X3 Gem/Vin vs
Gem/Cis
Gem/Vino vs
Gem/Cap
Gem/Cis vs
Gem/Cap
N%N%N% P -value P-value P-value
Haematologic
Neutropenia 7 16.7 2 4.4 0.07 0.004 0.49
Febrile neutropenia
Anaemia 1 2.4 4 8.9 1 2.0 0.36 1 0.19
Thrombopenia 2 4.8 3 6.7 2 4.1 1 1 0.67
Non-haematological
Alopaecia
Fatigue
Nausea 2 4.8 2 4.4 2 4.1 1 1 1
Vomiting 1 2.4 3 6.7 3 6.1 0.62 0.62 1
Mucositis
Constipation
Diarrhoea 1 2.2 1 1 0.47
Infection
Myalgia
Sensory neuropathy
Mot. neuropathy
Bone pain 1 2.4 0.48 0.46 1
Dyspnoea 1 2.4 5 11.1 2 4.1 0.20 1 0.25
Abdominal pain
Oedema 1 2.0 1 1 1
Rash
Hand–foot syndr. 1 2.0 1 1 1
Dermatology 2 4.1 1 0.5 0.5
Creatinine
ALT (GPT)
AST (GOT) 3 6.1 1 0.25 0.24
AP 1 2.4 1 2.0 0.48 1 1
Bilirubin 1 2.0 1 0.48 1
Abbreviations: ALT¼alanine transaminase; AP¼alkaline phosphatase; AST¼aspartate transaminase; GOT¼glutamate oxalacitate transaminase; GPT¼glutamate pyruvate
transaminase; MOT¼motoric. P-values are calculated by Fishers exact test.
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sShehata et al, 2010). It is important to point out that efficacy is
maintained particularly in patients with TNBC (Koshy et al, 2010).
This applies in particular for the study arms containing cisplatin
and capecitabine.
Besides a negligible decrease in dose intensity of the GemCis
arm and a slightly increased rate of grade 3 and 4 neutropenia, the
toxicity profile among the three study arms seems comparable.
None of the recruited patients developed febrile neutropenia,
which emphasises the tolerability of the schedules. Comparing all
the toxicities that occurred within the present trial with previously
published trials that investigated one of the combinations for MBC,
there are some strong distinctions regarding the toxicity profile
and in particular the rate of severe neutropenia. These discre-
pancies are partly explained by differences within the doses that
were applied in these trials. Therefore, drawing a final conclusion
outside a comparative trial is virtually impossible.
In conclusion, this randomised phase II trial has revealed
comparable results for all three gemcitabine-based regimens
regarding efficacy and toxicity. Gemcitabine-based chemotherapy
appears to be a notable treatment option for pretreated patients
with MBC.
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